Identification of FDA-approved drugs that induce heart regeneration in mammals.
Nat Cardiovasc Res
; 3(3): 372-388, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-39183959
ABSTRACT
Targeting Meis1 and Hoxb13 transcriptional activity could be a viable therapeutic strategy for heart regeneration. In this study, we performd an in silico screening to identify FDA-approved drugs that can inhibit Meis1 and Hoxb13 transcriptional activity based on the resolved crystal structure of Meis1 and Hoxb13 bound to DNA. Paromomycin (Paro) and neomycin (Neo) induced proliferation of neonatal rat ventricular myocytes in vitro and displayed dose-dependent inhibition of Meis1 and Hoxb13 transcriptional activity by luciferase assay and disruption of DNA binding by electromobility shift assay. X-ray crystal structure revealed that both Paro and Neo bind to Meis1 near the Hoxb13-interacting domain. Administration of Paro-Neo combination in adult mice and in pigs after cardiac ischemia/reperfusion injury induced cardiomyocyte proliferation, improved left ventricular systolic function and decreased scar formation. Collectively, we identified FDA-approved drugs with therapeutic potential for induction of heart regeneration in mammals.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Regeneration
/
Homeodomain Proteins
/
Myocytes, Cardiac
/
Cell Proliferation
/
Myeloid Ecotropic Viral Integration Site 1 Protein
Limits:
Animals
Country/Region as subject:
America do norte
Language:
En
Journal:
Nat Cardiovasc Res
Year:
2024
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom